These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 11494334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 4. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Int J Oncol; 2007 Nov 01; 31(5):1223-30. PubMed ID: 17912451
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K.
    Am J Physiol Endocrinol Metab; 2004 Jun 01; 286(6):E927-31. PubMed ID: 14761877
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y, Wolff DW, Lin MF, Tu Y.
    Mol Pharmacol; 2007 Jul 01; 72(1):73-85. PubMed ID: 17430995
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL.
    Prostate; 2008 Dec 01; 68(16):1763-72. PubMed ID: 18729085
    [Abstract] [Full Text] [Related]

  • 9. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 10. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW.
    Cancer Res; 1993 Jun 15; 53(12):2852-7. PubMed ID: 7684949
    [Abstract] [Full Text] [Related]

  • 11. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 12. Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells.
    Sica G, Iacopino F, Settesoldi D, Zelano G.
    Eur Urol; 1999 Oct 15; 35 Suppl 1():2-8. PubMed ID: 10081696
    [Abstract] [Full Text] [Related]

  • 13. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW.
    Cancer Res; 1992 Mar 15; 52(6):1598-605. PubMed ID: 1371718
    [Abstract] [Full Text] [Related]

  • 14. Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells.
    Sica G, Zelano G, Settesoldi D, Iacopino F.
    Anticancer Res; 2003 Mar 15; 23(2B):1283-7. PubMed ID: 12820384
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 1999 May 01; 59(9):2136-41. PubMed ID: 10232600
    [Abstract] [Full Text] [Related]

  • 16. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
    Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.
    Mol Cell Endocrinol; 2007 May 30; 270(1-2):8-16. PubMed ID: 17434257
    [Abstract] [Full Text] [Related]

  • 17. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G.
    Clin Cancer Res; 2005 Jan 01; 11(1):49-57. PubMed ID: 15671527
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.